Dr. Jesse L. Goodman | Chief Scientist
FDA

Dr. Goodman became Chief Scientist and Deputy Commissioner for Science and Public Health of the FDA in 2009. He has broad responsibility for and engagement in leadership and coordination of the Agency’s cross-cutting scientific and public health efforts. From 2003-2009, he was Director of FDA’s Center for Biologics Evaluation and Research (CBER), which oversees medical and public health activities critical to US and global preparedness concerning the development, evaluation, safety, quality and availability of biologics. A graduate of Harvard, he received his M.D. from the Albert Einstein College of Medicine and did residency and fellowship training at the Hospital of the University of Pennsylvania and at UCLA (where he was also Chief Medical Resident). Prior to joining FDA, he was Professor of Medicine and Chief of Infectious Diseases at the University of Minnesota, where he directed the multi-hospital Infectious Diseases research, training and clinical programs, and where his NIH funded laboratory first isolated and characterized Anaplasma phagocytophilum, the infectious agent causing a new tick borne disease, human granulocytic ehrlichiosis. He has authored numerous scientific papers and edited the book “Tick Borne Diseases of Humans” published by ASM Press in 2005. Dr. Goodman has been elected to the American Society for Clinical Investigation and to the Institute of Medicine of the National Academy of Sciences, where he is a longstanding member of the Forum on Emerging Threats. He is an active clinician and teacher who is Board Certified in Internal Medicine, Oncology and Infectious Diseases and is Staff Physician and Infectious Diseases Consultant at both the National Naval and Walter Reed Army Medical Centers, and is Adjunct Professor of Medicine at the University of Minnesota.